Xoma reported $0 in Loan Capital for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Agios Pharmaceuticals AGIO:US $ 1.06M 0.78M
Biomarin Pharmaceutical BMRN:US $ 1081.05M 0.99M
Bluebird Bio BLUE:US $ 0M 0M
Celldex Therapeutics CLDX:US $ 0M 0M
Chimerix CMRX:US $ 0 0
Curis CRIS:US $ 0M 0M
Eli Lilly And LLY:US $ 14692M 460.9M
Emergent Biosolutions EBS:US $ 793.6M 7.9M
Epizyme EPZM:US $ 232.9M 411K
Intercept Pharmaceuticals ICPT:US $ 713.86M 3.03M
Life Technologies LIFE:US $ 0.3M 0.3M
Macrogenics MGNX:US $ 0 0
Novartis NVS:US $ 23784M 589M
Novartis NOVN:VX SF 23784M 589M
Prothena PRTA:US 0 0
Regeneron Pharmaceuticals REGN:US $ 2700.7M 0.3M
Teva Pharmaceutical Industries TEVA:US $ 20363M 477M
Xoma XOMA:US $ 0 0
YTE INCY:US $ 31.16M 0.23M